Literature DB >> 2713972

Progressive improvement in pulmonary vascular resistance after percutaneous mitral valvuloplasty.

M J Levine1, J S Weinstein, D J Diver, A D Berman, R M Wyman, M J Cunningham, R D Safian, W Grossman, R G McKay.   

Abstract

Percutaneous mitral valvuloplasty has been proposed as a nonsurgical technique for treating high-risk patients with mitral stenosis who are deferred from mitral valve replacement. The effect of this technique on patients with pulmonary hypertension, however, has not been fully evaluated. Accordingly, serial assessment of pulmonary vascular resistance was made in 14 patients with critical mitral stenosis and pulmonary hypertension (pulmonary vascular resistance greater than 250 dynes.sec/cm5 or mean pulmonary artery pressure greater than 40 mm Hg or both) who underwent percutaneous balloon dilatation of the mitral valve. Balloon valvuloplasty was performed with either one (n = 10) or two (n = 4) balloons through the transseptal approach, and it resulted in significant improvement in mean mitral gradient (from 18 +/- 4 to 9 +/- 4 mm Hg, p less than 0.001), systemic blood flow (from 3.7 +/- 1.2 to 5.0 +/- 2.2 l/min, p less than 0.001), and calculated mitral valve area (from 0.7 +/- 0.2 to 1.6 +/- 0.7 cm2, p less than 0.001). Immediately after balloon mitral valvuloplasty, pulmonary vascular resistance fell from 630 +/- 570 to 447 +/- 324 dynes.sec/cm5. Repeat catheterization 7 +/- 4 months after valvuloplasty showed further improvement of pulmonary hypertension in 12 of the 14 patients, with a mean pulmonary vascular resistance for the group as a whole of 280 +/- 183 dynes.sec/cm5, p less than 0.005. In two patients, mitral valve restenosis to a mitral valve area less than 1.0 cm2 was associated with a return of pulmonary hypertension to predilatation values.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2713972     DOI: 10.1161/01.cir.79.5.1061

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Hoarseness of Voice in a Patient with Mitral Stenosis and Ortner's Syndrome.

Authors:  Abdul Latiff Mohamed; Mollyza Mohd Zain
Journal:  Malays J Med Sci       Date:  2004-07

2.  Balloon dilatation of the mitral valve by a single bifoil (2 x 19 mm) or trefoil (3 x 15 mm) catheter.

Authors:  J Patel; S Vythilingum; A S Mitha
Journal:  Br Heart J       Date:  1990-11

3.  Predictors of persistent pulmonary hypertension after mitral valve replacement.

Authors:  Sem Briongos Figuero; José Luis Moya Mur; Alberto García-Lledó; Tomasa Centella; Luisa Salido; Álvaro Aceña Navarro; Ana García Martín; Ignacio García-Andrade; Enrique Oliva; José Luis Zamorano
Journal:  Heart Vessels       Date:  2015-06-09       Impact factor: 2.037

Review 4.  Pulmonary hypertension caused by pulmonary venous hypertension.

Authors:  Thomas J Kulik
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

5.  Pulmonary blood flow and pulmonary hypertension: Is the pulmonary circulation flowophobic or flowophilic?

Authors:  Thomas J Kulik
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

6.  Pulmonary hypertension related to left-sided cardiac pathology.

Authors:  Todd L Kiefer; Thomas M Bashore
Journal:  Pulm Med       Date:  2011-05-29

7.  Persistent pulmonary artery hypertension in patients undergoing balloon mitral valvotomy.

Authors:  Krishna Kumar Mohanan Nair; Harikrishnan Sivadasan Pillai; Thomas Titus; Ajitkumar Varaparambil; Sivasubramonian Sivasankaran; Kavassery Mahadevan Krishnamoorthy; Narayanan Namboodiri; Bijulal Sasidharan; Anees Thajudeen; Sanjay Ganapathy; Jaganmohan Tharakan
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

8.  Persistence of pulmonary arterial hypertension after relief of left sided obstructive lesions in small infants: our experience.

Authors:  T Munesh
Journal:  Images Paediatr Cardiol       Date:  2017 Jan-Mar

9.  Pulmonary hypertension in left heart disease.

Authors:  Pratishtha Mehra; Vimal Mehta; Rishi Sukhija; Anjan K Sinha; Mohit Gupta; M P Girish; Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2017-07-17       Impact factor: 3.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.